Spinal Vascular Disorder Nos, Overactive Bladder
Conditions
Keywords
Spinal Vascular Disorder, Overactive Bladder
Brief summary
The investigators' goal is to compare the efficacy of three different management strategies (sacral neuromodulation, botulinum toxin, M receptor antagonist) in treating consistent OAB in patients with SVMs after surgery.
Detailed description
Spinal Vascular malformations (SVMs) are complex neurosurgical lesions and account for 3%-4% of all intradural spinal cord mass lesions, which can influence the function of bladder. The investigators' goal is to compare the efficacy of three different management strategies (sacral neuromodulation, botulinum toxin, M receptor antagonist) in treating consistent OAB (Overactive Bladder) in patients with SVMs after surgery.
Interventions
PROCEDUREsurgery
patients with SVMs receive surgery
PROCEDUREsacral neuromodulation
sacral neuromodulation (SNM) with InterStimTM
PROCEDUREbotulinum toxin A injection
BOTOX
DRUGM receptor antagonist
Tolterodine
Sponsors
Xuanwu Hospital, Beijing
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* •Patient diagnosed with spinal vascular diseases including Intradural arteriovenous malformation,Intradural arteriovenous fistula,Dural arteriovenous fistula,Extradural arteriovenous malformation,Paravertebral arteriovenous malformation,Paravertebral arteriovenous fistula,cobbs' syndrome,and other spinal arteriovenous metameric syndromes involve the spinal cord. * patient not received surgical or interventional treatment before * patient with normal cardiac, renal and hepatic function * patient capable of understanding the content of the patient information / Informed Consent Form * patient willing and able to participate in the registry * patients have consistent OAB after surgery
Exclusion criteria
* •patient received surgical treatment or interventional treatment before * patient is pregnant * patient allergic to iodine * patient unable to complete follow-up * patient with cerebral lesions * patient with other spinal lesions * patient with cardiac, renal or hepatic dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| bladder function | 3 months and 12 months | bladder function change in urodynamics |
Contacts
Primary Contactzhenhua shang, M.D
Outcome results
None listed